Melanoma: What is after immunotherapy? More immunomodulation?

> Sanjiv S. Agarwala, MD Professor, Temple University School of Medicine

Current Status of First-line Therapy

- BRAF Mutated
 - Targeted therapy
 - Combo BRAF/MEK
 - Combo anti-PD1/targeted (triple therapy)
 - Immunotherapy
 - Single agent anti-PD1
 - Combo anti-PD1/CTLA-4 (Ipi/Nivo)
 - Combo anti-PD1/LAG-3 (Nivo/Relatlimab)


Current Status of First-line Therapy

- BRAF WT
 - Immunotherapy
 - Single agent anti-PD1
 - Combo anti-PD1/CTLA-4 (Ipi/Nivo)
 - Combo anti-PD1/LAG-3 (Nivo/Relatlimab)


Clinical Issue

- Immunotherapy is most likely going to be used in all patients with advanced melanoma
- What to do after immunotherapy is an important clinical question

Previous Therapy



Previous Therapy



After Failure of Combo Immunotherapy

- LAG-3 plus PD-1
- Cellular Therapy
- Lenvatinib + PD-1
- Epigenetic Modification

After Failure of Combo Immunotherapy

- LAG-3 plus PD-1
- Cellular Therapy
- Lenvatinib + PD-1
- Epigenetic Modification

LAG3 + PD-1 is Minimally Effective in PD-(L)1 Refractory Melanoma

Relatlimab + Nivolumab 11.5% ORR (n=61) [1]

Fianlimab + Cemiplimab 13.3% ORR (n=15) [2]

[1] Ascierto et al. ESMO 2017[2] Hamid et al. ESMO 2022

Study design: three serial expansion cohorts in advanced melanoma setting

Treatment:

Fianlimab 1600 mg + cemiplimab 350 mg IV every 3 weeks, for up to 51 weeks*

Initial cohort MM1[#] (n=40)

1L or 2L advanced melanoma patients who have never received anti-PD-(L)1

Confirmatory cohort MM2[#] (n=40)

1L advanced melanoma patients who have never received anti-PD-(L)1

PD-1 experienced cohort MM3[#] (n=18)

1L advanced melanoma patients with prior (neo)adjuvant systemic therapy[†], including 13/18 patients who received anti-PD-1

Primary endpoint

• ORR per RECIST 1.1 criteria

Secondary endpoints

- PFS
- DoR
- DCR
- Safety
- PK

Key inclusion criteria

- Metastatic or inoperable locally advanced non-uveal melanoma
- ≥18 years of age
- · ECOG PS of 0 or 1
- At least one lesion measurable by RECIST 1.1

Key exclusion criteria

- · Uveal melanoma
- Prior treatment with a LAG-3 targeting agent
- Radiation therapy within 2 weeks prior to enrollment

MM1⁴, Cohort 5, IMM2⁴, Cohort 15, IMM3⁴, Cohort 16, I/Vith an option for an additional 51 weeks; Thrior exposure to (neo)adjuvant systemic treatment (including anti-PD-1) with recurrence >6 months after adjuvant therapy, Immuno additional to the control state to additional 51 weeks; Thrior exposure to (neo)adjuvant systemic treatment (including anti-PD-1) with recurrence >6 months after adjuvant therapy, Immuno additional to additional to additional 51 weeks; Thrior exposure to (neo)adjuvant systemic treatment (including anti-PD-1) with recurrence >6 months after adjuvant therapy.

1L, first line; 2L, second line; DCR, disease control rate; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance score; IV, intravenous; LAG-3, lymphocyte activation gene-3; MM, metastatic melanoma; NHL, non-Hodgkin lymphoma; ORR, objective response rate; PD-(L)1, programmed cell death-(ligand)1; PFS, progression-free survival; PK, pharmacokinetics; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1.

Tumor response by cohort

Response endpoints	Initial cohort MM1 [#] (n=40)	Confirmatory cohort MM2 [#] (n=40)	PD-1 experienced cohort MM3 [#] (n=18)*
Median follow-up (IQR), months	20.8 (11.2–30.8)	11.5 (8.9–13.9)	9.7 (4.8–14.1)
Treatment exposure, median (IQR), weeks	37 (20–81)	35 (15–51)	23 (12–37)
ORR, (n)	63% (25)	63% (25)	56% (10)
95% CI for ORR	(46–77)	(46–77)	(31–79)
DoR, median (95% Cl), months	NR (12–NE)	NR (NE-NE)	NR (6–NE)
DCR, (n)	80% (32)	80% (32)	67% (12)
95% CI for DCR	(64–91)	(64–91)	(41–87)
Best overall response, (n)			
CR	15% (6)	13% (5)	6% (1)
PR	48% (19)	50% (20)	50% (9)
SD	18% (7)	18% (7)	11% (2)
PD	15% (6)	15% (6)	28% (5)
NE	5% (2)	5% (2)	6% (1)
KM-estimated PFS, median (95% CI), months	24 (4–NE)	15 (7–NE)	12 (1–NE)

MM1#, Cohort 6; MM2#, Cohort 15; MM3#, Cohort 16. *17 patients in cohort MM3 received prior adjuvant therapy and 1 patient in cohort MM3 received prior neoadjuvant therapy.

CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; IQR, interquartile range; KM, Kaplan-Meier; MM, metastatic melanoma; n, number; NE, not estimated; NR, not reached; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.


After Failure of Combo Immunotherapy

- LAG-3 plus PD-1
- Cellular Therapy
- Lenvatinib + PD-1
- Epigenetic Modification

Tumor-infiltrating lymphocytes (TIL)

Preparation and treatment

PARIS




Single infusion

Administration of

TIL therapy in aPD1 resistant melanoma patients


Clinical efficacy of cryopreserved TIL product - Lifileucel



Response rate 36 % OR 3%


Lifileucel cryopreseved TIL product from lovance Production time 22 days.

Durability of response



PARIS ESVO

Progression after anti-PD-1: TIL Therapy with Lifileucel



(Sarnaik et al. *J Clin Oncol* 2021)

2022 ASCO


ANNUAL MEETING

#ASC022

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.



Trial design




Primary endpoint: Progression-free survival (PFS) according to RECIST 1.1 per investigator review in the intention-to-treat population (ITT)*

*Using the stratified (unweighted) log-rank test and the stratified cox regression model. The study was considered to be positive when PFS after TIL is significantly longer than ipilimumab, based on the log-rank test with a two-sided p-value below 0.05.



Results (1)

Progression-free survival according to RECIST 1.1 in the ITT population




PARIS ESVO

Results (2)

Best overall response according to RECIST 1.1*

	TIL (n=84)	lpilimumab (n=84)
Best overall response	n (%)	n (%)
Complete response	17 (20.2)	6 (7.1)
Partial response	24 (28.6)	12 (14.3)
Stable disease	16 (19.1)	15 (17.9)
Progressive disease	24 (28.6)	40 (47.6)
Not evaluable/done#	3 (3.6)	11 (13.1)
Overall response [†]	41 (48.8)	18 (21.4)
Clinical benefit [‡]	57 (67.9)	33 (39.3)


*In the intention-to-treat population. #In 3 (3.6%) and 11 (13.1%) of TIL and ipilimumab treated patients, respectively, best radiologic response could not be evaluated or was not done due to an event (death or need to start subsequent anticancer therapy) before the moment of first response evaluation or due to unevaluable target lesions in follow-up. *Defined as CR plus PR and *CR, PR plus SD according to RECIST 1.1.






Results (3)

Overall survival in the ITT population





Median

overall survival

2 year

overall

95% CI

44.0 - 67.3

33.7 - 57.8

95% CI



Next-generation strategies





Figure 2.

Strategies to optimize T-cell activation in next-generation TIL. Immune-modulation strategies involve improvements in intracellular and extracellular signaling.

Betof Warner CCR 2023

Precision' TIL therapy - targeting clonal neoantigens




After Failure of Combo Immunotherapy

- LAG-3 plus PD-1
- Cellular Therapy
- Lenvatinib + PD-1
- Epigenetic Modification



VEGFR Signaling Can Lead to an Immunosuppressive State in the Tumor Microenvironment




- VEGF modulates the function of T-cells, suppressive immune cells, and stroma in the tumor microenvironment
- Early studies in metastatic melanoma suggest a rationale for combining VEGF inhibitors with immune checkpoint inhibitors

LEAP-004 Study Design (NCT03776136)

Participants

- Unresectable stage III or IV melanoma^a
- Confirmed PD per iRECIST^{1b} on or within 12 wk of last dose of anti–PD-1/L1 given alone or in combination (including with anti–CTLA-4) for ≥2 doses
 - ≤25% with PD on anti–CTLA-4 + anti–PD-1/L1
- No limit to number of previous therapies
- Measurable disease confirmed by blinded, independent central review (BICR)



^aPer AJCC 8th edition. ^bIn the absence of rapid clinical progression, initial evidence of radiologic PD required confirmation by a second assessment performed ≥4 weeks from first documented radiographic PD. ^cEligible patients deriving clinical benefit can be treated beyond PD. Participants with CR can discontinue study treatment if they have received it for ≥24 weeks. ^dModified to follow ≤10 target lesions total and ≤5 target lesions per organ. 1. Seymour L et al. *Lancet Oncol* 2017;18:e143-52.


BICR-Confirmed Response by RECIST v1.1

	Total Population N = 103	
ORR, % (95% CI)	21.4% (13.9-30.5)	Compared With Initial Analysi
DCR, % (95% CI)	66.0% (56.0-75.1)	ORR remained the same 1 additional CR
Best overall response, n (%)		DCR increased from
CR	3 (2.9%)	65.0% to 66.0%
PR	19 (18.4%)	 1 additional SD
SD	46 (44.7%)	
PD	30 (29.1%)	
Not assessed ^a	5 (4.9%)	

^aParticipants who had no post-baseline imaging assessments. Data cutoff date: Sep 18, 2020.

1. Arance A et al. Ann Oncol 2020;31(suppl_4): S1142-S1215 [Abstr LBA44].


Duration of BICR-Confirmed Response by RECIST v1.1



^aPatients who died or had PD. Data cutoff date: Sep 18, 2020.

1. Arance A et al. Ann Oncol 2020;31(suppl_4): S1142-S1215 [Abstr LBA44].

Best Change From Baseline in Target Lesions (RECIST v1.1 by BICR)




^aThe 8 participants who did not have ≥1 post-baseline imaging assessment evaluable for change from baseline in target lesions are excluded from the graph. Data cutoff date: Sep 18, 2020.

After Failure of Combo Immunotherapy


- LAG-3 plus PD-1
- Cellular Therapy
- Lenvatinib + PD-1
- Epigenetic Modification

Proposed MOA of HDAC inhibition as IO


- Entinostat (ENT) is an oral class Iselective histone deacetylase inhibitor
- ENT reduces MDSC and Treg number & function
- ENT induces pro-inflammatory cascade in TME
- ENT enhances antigen presentation
- Additional beneficial effects on Teff & NK cells
- Synergy with anti-PD1 inhibition in preclinical models



ENCORE-601: Open-Label Study Evaluating ENT + PEMBRO in Patients With Recurrent or Metastatic Melanoma and Prior Progression On or After Anti-PD-1 Therapy



ENT plus pembro is associated with durable responses in patients who previously progressed on anti-PD-1 therapy



- 10 confirmed responses of 53 treated [19% ORR (95% CI: 9%-32%)]
 - 1 CR, 9 PRs
- Median duration of response: 13 months (range 3-20)
 - 4 responders ongoing
- An additional 9 patients have had SD for >6 months
 - 36% CBR (95% CI: 23%-50%)

There's a Lot Going On!

ANTI-LAG-3 DEVELOPMENT

Drug	Study phase	Cancer type	Combination
relatlimab	Phase 1,2, and 3	Solid tumors Haematological malignancies	nivolumab
LAG525/ leramilimab	Phase 1, 2	Solid tumors Haematological malignancies	spartalizumab
MK4280	Phase 1	Solid tumors	pembrolizumab
REGN3767	Phase 1	Solid tumors	cemiplimab (anti-PD-1)
MGD013	Phase 1	Solid tumors Haematological malignancies	-
TSR-033	Phase 1	Solid tumors	Anti-PD-1
BI754111	Phase 1	Solid tumors	BI754091 (anti-PD-1)
INCAGN02385	Phase 1	Solid tumors	Solid tumors
IMP321/ Eftilagimod alpha	Phase 1,2	Solid tumors	pembrolizumab, chemotherapy
LBL-007	Phase 1	Melanoma	Toripalimab
IBI110	Phase 1	Solid tumors	Sintilimab (anti-PD-1)




Trial number	Drug name	Trial description	Study endpoints	Patients	
CA022-0011	BMS-986218	Phase 1/2a first-in-human study of anti–CTLA-4 NF monoclonal antibody alone and in combination with nivolumab in advanced solid tumors	Safety, PK, PD, preliminary antitumor activity	Advanced solid tumors, including metastatic melanoma and NSCLC after anti–PD-1/PD-L1 therapy ²	
CA030-001 ^{3,4}	BMS-986249	Phase 1/2 first-in-human study of anti–CTLA-4 PB alone and in combination with nivolumab in advanced solid tumors	Safety, PK, PD, preliminary antitumor activity	Advanced solid tumors, including metastatic melanoma, HCC, CRPC, TNBC	
CA043-001 ⁵	BMS-986288	Phase 1/2 first-in-human study of anti–CTLA-4 NF PB alone and in combination with nivolumab in advanced malignant tumors	Safety, PK, PD, preliminary antitumor activity	Advanced solid tumors	

Probody is a US registered trademark of CytomX Therapeutics, Inc.

1. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03110107. Accessed February 4, 2021; 2. Friedman C, et al. Poster presented at the SITC 2020 Annual Virtual Meeting; November 9-14, 2020; 3. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03369223. Accessed February 4, 2021; 2. Friedman C, et al. Poster presented at the SITC 2020 Annual Virtual Meeting; November 9-14, 2020; 3. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03369223. Accessed February 4, 2021; 4. CytomX Therapeutics. Press release. https://www.globenewswire.com/news-release/2020/06/22/2051270/0/en/CytomX-Therapeutics-Announces-Preclinical-Data-from-anti-CTLA-4 -Probody-Therapeutic-Programs-Presented-by-Partner-Bristol-Myers-Squibb-at-AACR-Annual-Meeting.html. June 22, 2020. Accessed February 4, 2021; 5. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03994601. Accessed February 4, 2021; 5. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03994601.

TIGIT: T-Cell Immunoreceptor with Ig and ITIM domains





CAR-TTrials in Melanoma

Target antigen	Disease	Modification	Country	Clinical Irials.gov identifier	Status
c-Met	melanoma, breast cancer	4-1BBζ CAR	United States	NCT03060356	recruiting
CD70	melanoma, pancreatic cancer, renal cell cancer, breast cancer, ovarian cancer	NA	United States	NCT02830724	recruiting
GD2	melanoma, sarcoma, osteosarcoma, neuroblastoma	28ΟΧ40ζ + ICD9 CAR	United States	NCT02107963	com- pleted
VEGFR2	metastatic cancer, melanoma, renal cancer	NA	United States	NCT01218867	com- pleted

ClinicalTuisle

4-1BBζ CAR, chimeric antigen receptor with 4-1BB co-stimulatory domain; 28OX40ζ CAR, chimeric antigen receptor with CD28 and OX40 costimulatory domains; ICD9, caspase dimerization domain; NA, not available.

What's After Immunotherapy?

Clinical Trials!